tbuckley/cabot-search huggingface dataset:
Cognitive symptoms in non-Hodgkin lymphoma survivors: Prevalence and discussion with doctors.
Authors: Neeraj K Arora, Roxanne E Jensen, Laura Pence Forsythe, Sandra A. Mitchell, Keith M Bellizzi, Noreen Aziz, Julia Howe Rowland, Ann S. Hamilton, Arnold L. Potosky
Journal: Journal of Clinical Oncology (2012)

9130 Background: Several studies have documented the negative impact of chemotherapy on patients’ cognitive functioning. However, this concern has been understudied among non-Hodgkin Lymphoma (NHL) survivors. Methods: We analyzed survey data from a population-based study of survivors diagnosed with aggressive NHL in Los Angeles County 2-5 years prior to the study; data were collected between 2003-2005. We assessed prevalence of cognitive symptoms (CS) by a single item screener that asked if in the past 6 months survivors experienced problems with memory, attention, or concentration; if yes, we asked if they discussed the problem with a doctor. Frequency of CS was assessed by a 4 item scale that measured how often survivors experienced different CS in the past 4 weeks (none, a little, some, most, all the time). Logistic regression analyses identified correlates of reporting CS (yes/no) as well as discussion with a doctor (yes/no). Analyses were based on data from 358 survivors who had received chemotherapy and saw a doctor for follow-up care in the past year. Results: 134/358 survivors (37%) reported CS, many reporting difficulty some, most, or all the time with memory (64%), attention (58%), concentration (57%), and problem solving (46%). Survivors with higher education, who were not married/partnered, and who had more comorbidities were more likely to report CS (p&lt;0.05 for all). Report of CS was not associated with age, NHL grade, time since completion of chemotherapy, or having been treated with radiation or bone marrow/stem cell transplant. Of the 134 survivors who reported CS, only 43% discussed them with a doctor. Survivors who reported being given information about late effects of treatment were more likely to discuss CS than those who were not (OR: 3.4, 95% CI 1.4-8.5, p&lt;0.01). Conclusions: One in three NHL survivors reported CS following chemotherapy; however, a majority did not discuss these with a doctor. Periodic screening for CS in NHL survivors may be needed and would provide an opportunity to improve patient-clinician communication about this issue. Additionally, research that identifies mechanisms that cause CS in this population is warranted in order to develop targeted behavioral and medical interventions.
FIRST-IN-MAN DEVELOPMENT OF A MACHINE LEARNING CARDIAC PHASE SPACE ANALYTIC APPROACH TO PREDICT ELEVATED LEFT VENTRICULAR PRESSURES
Authors: Rola Khedraki, Tim Burton, Travis Cohoon, Christine Shen, Ali Khosousi, Emmanuel Lange, William E. Sanders, Sanjeev Bhavnani
Journal: Journal of the American College of Cardiology (2020)
DURABILITY OF TREATMENT WITH ANTIARRHYTHMIC DRUGS FOR NEW-ONSET ATRIAL FIBRILLATION IN A NATIONWIDE POPULATION UNDER AGE 65
Authors: Robert D'Angelo, Motiur Rahman, Rahul Khanna, Robert W. Yeh, Laura Goldstein, Iftekhar Kalsekar, Stephen Marcello, Patricia Tung, Peter J. Zimetbaum
Journal: Journal of the American College of Cardiology (2020)
PERSISTENT REVERSED FLOW AND ANTEGRADE SLOW FLOW OF THE RIGHT CORONARY ARTERY WITH ANOMALOUS ORIGIN FROM THE LEFT SINUS ARE THE MECHANISMS FOR CHEST PAIN AND SUDDEN DEATH
Authors: Luan M. Ngo, Duy Chung, An Ngo, Thach Nguyen, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2020)
ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION USING DRUG-ELUTING STENTS IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Wenbin Lu, Yu Wang, Lijuan Chen, Yongjun Li, Rui Zhang, Zhongpu Chen, JInchuan Yan, Mingming Yang, Bing Han, Zhirong Wang, Shenghu He, Lianglong Chen, Xiang Wu, Hesong Zeng, Likun Ma, Guoping Shi, Jianrong Yin, Lulu Sun, Yuyu Yao, Jiyan Chen, Genshan Ma
Journal: Journal of the American College of Cardiology (2020)
Combination of bevacizumab (A) and pegylated-liposomal doxorubicin (PLD) (PLD-A) in sarcoma (SAR)
Authors: P. A. Haddad, K. M. Skubitz
Journal: Journal of Clinical Oncology (2006)

9556 Background: Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis (AG) in many tumors including SAR. A has demonstrated efficacy in several common solid tumors. Because of the known efficacy of PLD in SAR and the presumed importance of VEGF in SAR, we have treated SAR patients with PLD-A. It is possible that the addition of A to PLD might alter the toxicity profile. To our knowledge, the toxicities of this combination have not been previously described. Methods: To better define the toxicity of the combination of PLD-A in SAR, we reviewed our experience with PLD-A in patients with SAR treated between 2004 and 2005. Results: We identified 12 patients with SAR treated with PLD-A at our institution. There were 5 men and 7 women, with a median age of 43.5 years (range 27–57). Nine patients initiated therapy with PLD on a 28 day interval at a median dose of 45 mg/m 2 (range 45–50), and 3 on a 14 day interval at a dose of 22.5 mg/m 2 , in combination with A at 5 mg/kg every 2 weeks. A median of 3 cycles was given (range 2–9). Standard CALGB response and NIH common toxicity criteria were used. Dose delay was required in 3 patients for the second cycle, and dose reduction was required in 5 patients by cycle 3. Of the 10 patients starting with monthly PLD, 6 were changed to q 2 week PLD by cycle 4. Mucositis and skin toxicity were the dose limiting toxicities (DLT) in 9/12 patients, and myelosuppression was the DLT in 1/12 patients. Conclusions: This report describes the toxicity profile of PLD-A in 12 patients with SAR. The toxicities observed were similar to those seen with PLD alone, however, there was a suggestion that these toxicities may be more pronounced with the addition of A, though this appears to vary among patients. Since VEGF is important for wound healing, the known effects of A on this process may contribute to more skin and mucosal toxicity of PLD at a given dose. Future studies of PLD-A should consider the potential of increased mucosal and skin toxicity, and the use of q2week PLD to allow more control over toxicity is suggested. [Table: see text]
COMPARISON OF OUTCOMES IN CATHETER-DIRECTED VERSUS ULTRASOUND-ASSISTED THROMBOLYSIS FOR TREATMENT OF PULMONARY EMBOLISM
Authors: Sorcha Allen, Katerina Porcaro, Lucas Chan, Dalila Masic, Stephen Morris, Jeremiah Haines, Verghese Mathew, Ferdinand Leya, Lowell Steen, John Lopez, Carlos Bechara, Jawed Fareed, Amir Darki, Yevgeniy Brailovsky
Journal: Journal of the American College of Cardiology (2020)
Covid-19: outbreak could last until spring 2021 and see 7.9 million hospitalised in the UK
Authors: Elisabeth Mahase
Journal: BMJ (2020)

The covid-19 outbreak is expected to last around one year (until spring 2021), with around 80% of the population infected and up to 15% of people (7.9 million) requiring hospitalisation in the UK, a briefing document produced by Public Health England for the government has said.

The document, seen by the Guardian , said that, of the five million people deemed vital because of their work “in essential services and critical infrastructure”—including one million NHS staff and 1.5 million social care staff—500 000 could be off sick at any one time. 

Overall, at least 10% of people in the UK will have a cough at any one time in the peak months. Those with a …
Primary ovarian granulocytic sarcoma: A case report and literature review.
Authors: Roland Fokwen Njoh
Journal: Journal of Clinical Oncology (2012)

e17011 Background: Granulocytic sarcoma, also known as myeloid sarcoma, myeloblastoma, and Chloroma are extramedullary manifestation of malignant myeloid precursor cells. Its occurrence as a primary ovarian tumor is a rare entity. Methods: A 49 y/o female presented to the clinic with right lower quadrant abdominal pain that had been present for 6 months. Eventually, a CT scan was obtained that showed a 6.5 cm mixed solid and cystic mass on the right adnexa that was felt to represent malignancy. Her history was positive for residing near a car-spraying garage. She was taken to the operating room and underwent a robotically assisted laparoscopic BSO, laparotomy, omentectomy, lymph node dissection and tumor debulking. Findings at surgery included a normal left ovary, adherent right ovary, normal omentum, nodular epiploicae, and tumor encasing the iliac vessels. Final pathology report of tumor cells showed granulocytic sarcoma with flow cytometry positive for CD 33 and CD 34. Bone marrow biopsy and peripheral blood flow cytometry was negative for leukemia. She subsequently underwent chemo-induction with cytarabine, idurubicin, and prednisone. Results: A PUBMED, MEDLINE/OVID database search revealed only three previously reported cases of primary ovarian granulocytic sarcoma without concurrent or subsequent hematological manifestation. Conclusions: Granulocytic sarcoma most frequently precedes or occurs in the setting of acute myeloid leukemia (AML), chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). The typical sites of isolated granulocytic sarcoma include bone, periosteum, soft tissues, and lymph nodes, and less commonly the orbit, intestine, mediastinum, epidural region, uterus, and ovary. In patients presenting with primary ovarian granulocytic sarcoma, the final diagnosis is obtained after tissue examination and often comes as a surprise to providers. Granulocytic sarcoma should therefore be included in the differential diagnosis of patients with isolated ovarian tumor.
VALIDATION OF LONG-TERM PERFORMANCE OF VTE-BLEED SCORE FOR MAJOR BLEEDING IN PATIENTS WITH VENOUS THROMBOEMBOLISMS: FROM THE COMMAND VTE REGISTRY
Authors: Yuji Nishimoto, Yugo Yamashita, Takeshi Morimoto, Syunsuke Saga, Yukihito Sato, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2020)
Testosterone levels as a prognostic factor for survival in patients with castrate-restistant prostate cancer (CRPC).
Authors: Alfonso Gomez de Liaño, José Pablo Maroto, Cristina Martin Lorente, Elena Cillan, Ismael Macias, Agostina Stradella, Ivana Sullivan, Paola Murata, Cristina Arqueros, Georgia Anguera, Dhiossett Condori, Agust Barnadas
Journal: Journal of Clinical Oncology (2012)

e15159 Background: To analyze the prognostic value for survival of the absolute levels of serum testosterone in patients under the definition of CRPC (PSA and/or clinical progression with a testosterone level below 50 ng/dL). Methods: 49 patients were included in 4 non-hormonal first line phase II-III trials in our institution since August 2006 until Jan 2012 for metastatic CRPC. Inclusion criteria of those trials uniformly required castrate levels of testosterone. Survival was calculated since the date of entrance in the trial. Results: Median age was 71 years (53-89). 9/49 (18%) of the patients had visceral metastases. Median PSA was 66.7 U/L (0.1-936). Median testosterone level was 11.54 ng/dL (range 0.2-49.9). All patients had metastatic prostate cancer, previous treatment consisted of at least 2 hormonal maneuvers (adding or stopping antiandrogen for a wash-up period of 42 days for bicalutamide). All patients received at least one line of chemotherapy for CRPC as part of the trial or after the completion of the trial. Median survival was 21.85 months. For 26 patients with a serum testosterone level below the median value, median survival was 17 months and 35.45 months for those patients with a testosterone level over 11.51 ng/dL (p value 0.036). Conclusions: Testosterone serum levels even under castration level (below 50 ng/dL) were a prognostic factor for survival in patients with metastatic prostate cancer considered castration resistant.
Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists
Authors: Michael Day
Journal: BMJ (2020)

Scientists and senior doctors have backed claims by France’s health minister that people showing symptoms of covid-19 should use paracetamol (acetaminophen) rather than ibuprofen, a drug they said might exacerbate the condition.

The minister, Oliver Veran, tweeted on Saturday 14 March that people with suspected covid-19 should avoid anti-inflammatory drugs. “Taking anti-inflammatory drugs (ibuprofen, cortisone . . .) could be an aggravating factor for the infection. If you have a fever, take paracetamol,” he said.

His comments seem to have stemmed in part from remarks attributed to an infectious diseases doctor in south west France. She was reported to have cited four cases of young patients with covid-19 and no underlying health problems who went …
ASSOCIATION BETWEEN INDIVIDUAL INCOME AND INCIDENCE OF HEART FAILURE SUBTYPES IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Andi Shahu, Oluseye Ogunmoroti, Victor Okunrintemi, Di Zhao, Vishal Rao, Lena Mathews, Chiadi Ndumele, Erin Michos
Journal: Journal of the American College of Cardiology (2020)
Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer: Experience in Mexican population.
Authors: Abdel Karim Dip Borunda, Eucario Leon Rodriguez, Alejandra Armengol Alonso
Journal: Journal of Clinical Oncology (2012)

e15567 Background: Primary debulking surgery is considered the standard of treatment in advanced ovarian cancer (AOC) while neoadjuvant chemotherapy is used in non resectable stages. Methods: We retrospectively analyzed 68 AOC cases from January 2000 to December 2011. 35 received neoadjuvant chemotherapy (NAC) while 33 were resected primarily and received adjuvant chemotherapy (AC). To compare both groups we used T standard test and 2 sided chi -squared. Non parametric variables were analyzed with U Mann – Whitney. Overall survival(OS) was analyzed using Kaplan Meier method with log rank test. We considered statistically significant p&lt;0.05. (SPSS v 17). Results: The median age was 60 (NAC) vs 53(AC) years respectively. The NAC group had more advanced stage disease (FIGO IIIC/IV stage; 71/29% vs 91/9%; p=0.04). The most frequent histologic subtype in both groups was serous - papillary and histologic grade was poorly differentiated in 71 vs 72% (p=0.41). At diagnosis the median levels of ca-125 were 1,896 U/ml for NAC group vs 768 U/ml for AC group (p=0.025). After the primary treatment received the median levels of ca – 125 were 29 U/ml vs 84 U/ml (p=0.76). Platin based chemotherapy was used in 95% vs 70% respectively. Complete resection of macroscopic disease was observed in 68% of NAC vs 63% in AC respectively. No statistical differences were observed in surgical time (median 192 min vs 204 min; p=0.55) and surgical bleeding (468 vs 510ml; p=0.79). Median survival time was 23 +/ - 26 months for neoadjuvant and 27+/- 35 months for primary surgery (p=0.56). In a subgroup analysis of patients who received 6 neoadjuvant cycles vs perioperatory chemotherapy (3 pre and 3 postoperatory) we observed a significant survival difference, with a median of 62 months (95% CI 12-38) vs 12 months (95% CI 54 – 178) respectively (p=0.010). Conclusions: Non inferior survival or differences in surgical outcomes were observed with neoadjuvant therapy. Significant survival increase was observed in patients who received complete chemotherapy schedule before surgery, this evidence allowed to design a prospective trial in our Institution.
Response to Comment on Šoupal et al. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-up From the COMISAIR Study. Diabetes Care 2020;43:37–43
Authors: Jan Šoupal, Christopher G. Parkin
Journal: Diabetes Care (2020)

We thank Telliam and Thivolet (1) for their interest in our study of the use of real-time continuous glucose monitoring (rtCGM) versus self-monitoring of blood glucose with insulin pumps and multiple daily insulin injection (MDI) therapy. However, we have some questions about their study findings.

First, it is impossible to assess the significance of their findings because they have not provided baseline values for comparison. Was there an increase or decrease in time spent with blood glucose <70 mg/dL?

Second, as shown in their Fig. 1, the time below range (TBR) ( 200 mg/dL). This suggests that while these MiniMed 640G users may have experienced less TBR, their percentage of time spent above range remained suboptimal. The recent CGM consensus report recommends a composite …
Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State
Authors: Matt Arentz, Eric Yim, Lindy Klaff, Sharukh Lokhandwala, Francis X. Riedo, Maria Chong, Melissa Lee
Journal: JAMA (2020)

Brad Spellberg, MD; Meredith Haddix, MPH; Rebecca Lee, MPH; Susan Butler-Wu, PhD; Paul Holtom, MD; Hal Yee, MD, PhD; Prabhu Gounder, MD
A quantitative super-resolution imaging toolbox for diagnosis of motile ciliopathies
Authors: Zhen Liu, Quynh P. H. Nguyen, Qingxu Guan, Alexandra Albulescu, Lauren Erdman, Yasaman Mahdaviyeh, Jasmine Kang, Hong Ouyang, Richard G. Hegele, Theo Moraes, Anna Goldenberg, Sharon D. Dell, Vito Mennella
Journal: Science Translational Medicine (2020)

Quantitative super-resolution imaging improves the diagnosis of primary ciliary dyskinesia.
Applying speech technologies to assess verbal memory in patients with serious mental illness
Authors: Terje B. Holmlund, Chelsea Chandler, Peter W. Foltz, Alex S. Cohen, Jian Cheng, Jared C. Bernstein, Elizabeth P. Rosenfeld, Brita Elvevåg
Journal: npj Digital Medicine (2020)

Verbal memory deficits are some of the most profound neurocognitive deficits associated with schizophrenia and serious mental illness in general. As yet, their measurement in clinical settings is limited to traditional tests that allow for limited administrations and require substantial resources to deploy and score. Therefore, we developed a digital ambulatory verbal memory test with automated scoring, and repeated self-administration via smart devices. One hundred and four adults participated, comprising 25 patients with serious mental illness and 79 healthy volunteers. The study design was successful with high quality speech recordings produced to 92% of prompts (Patients: 86%, Healthy: 96%). The story recalls were both transcribed and scored by humans, and scores generated using natural language processing on transcriptions were comparable to human ratings (R = 0.83, within the range of human-to-human correlations of R = 0.73-0.89). A fully automated approach that scored transcripts generated by automatic speech recognition produced comparable and accurate scores (R = 0.82), with very high correlation to scores derived from human transcripts (R = 0.99). This study demonstrates the viability of leveraging speech technologies to facilitate the frequent assessment of verbal memory for clinical monitoring purposes in psychiatry.
IMPROVED PHARMACOLOGIC PROFILE OF A NOVEL, LIQUID ASPIRIN FORMULATION COMPARED WITH ENTERIC COATED ASPIRIN-A POOLED, PATIENT LEVEL ANALYSIS OF TWO RANDOMIZED CROSSOVER STUDIES
Authors: Deepak L. Bhatt, Dominick J. Angiolillo, Philippe Gabriel Steg, Weihong Fan, Carey Kimmelstiel, Roxana Mehran, George D. Dangas, Jayne Prats, Efthymios Deliargyris
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION OF LIPOPROTEIN(A) AND FIBRINOGEN AS PROGNOSTIC PREDICTORS FOR CARDIOVASCULAR OUTCOME IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: A PROSPECTIVE, LARGE COHORT STUDY
Authors: Yan Zhang, Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Hui-Wen Zhang, Rui-Xia Xu, Yuan-Lin Guo, Na-Qiong Wu, Gao Ying, Chuan-Jue Cui, Liu Geng, Qian Dong, Jing Sun, Jian-Jun Li
Journal: Journal of the American College of Cardiology (2020)
A phase II study of triapine in combination with gemcitabine (G) in patients (pts) with unresectable or metastatic pancreatic cancer (PC)
Authors: E. Greeno, H. L. Kindler, M. Peeters, R. C. Trowbridge, G. Chong, J. W. Valle, B. Johnson, E. L. Allain, H. A. Burris
Journal: Journal of Clinical Oncology (2006)

4123 Background: Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone [T]) is a small molecule that inhibits ribonucleotide reductase at a site distinct from G. In tumor cell lines, pre-exposure to T enhances G uptake and DNA incorporation, and yields synergistic cytotoxicity. A phase I trial of T + G showed that the combination was well-tolerated and produced T serum concentrations sufficient to modulate G activity in vitro (Ca Chemother Pharmacol, 2004). Methods: We conducted a phase II trial of T + G in advanced PC pts at 7 centers. Eligible pts were untreated, had measurable disease and ECOG PS 0–2. T was given by 4-hr infusion followed by G 1000 mg/m 2 on days 1, 8, and 15 of a 4-week schedule. Since preclinical studies showed longer exposure of T maximized synergy between the agents, the protocol was amended to administer T over 24 hrs continuously (CI) prior to G. Pts were assessed for response q 2 cycles and retreated to progression or toxicity. Results: Sixty pts (median age 62, range 37–88) were treated with T by 4-hr infusion (median 4 cycles, range 1–18). Pt characteristics included M:F 39/21; PS 0/1/2 = 25 (42%)/34 (57%)/1 (2%); metastatic/locally advanced 72/28%. Eight (15%) patients achieved PR; and 32 (60%) had stable disease. Median survival was 8 mos; 13% are alive at 1 yr. The next 6 pts (median age 54, range 50–69, M/F: 3/3) received T at a fixed dose of 400mg CI + G. Two pts were evaluable for response; 1 pt had PD, 1 pt is on treatment after 14 cycles. Due to excessive myelosuppression the dose of T CI was reduced to 105 mg/m 2 . Of 7 pts (median age 60, range 34–73) treated, 2 had PD, 1 was unevaluable, and 4 remain on tx. T toxicity included hypotension, hypoxia, rash and dyspnea in &lt; 10% of pts. In the 2 CI groups (N=13), the only toxicity attributed to T was excessive myelosuppression, requiring G dose reduction in all pts. Survival data on CI pts pending. Conclusions: T + G shows activity in PC. As predicted by preclinical studies, prolonged exposure (CI) enhances biological effect of T + G evidenced by increased myelosuppression without additional toxicities. Further studies are warranted to define the optimal dose of T CI with G. [Table: see text]